IBRX Latest Headlines

ImmunityBio Advances HPV-Positive Head and Neck Cancer Trial, Setting Up a New Catalyst for IBRX Investors

at www.tipranks.com (Thu, 4-Jun 12:32 PM)

Analysts Offer Insights on Healthcare Companies: ImmunityBio (IBRX), Abivax SA Sponsored ADR (ABVX) and Precigen (PGEN)

at www.tipranks.com (Tue, 2-Jun 7:10 AM)

ImmunityBio Faces Class Action Lawsuit Alleging Misleading Statements About Anktiva Capabilities—What Should Investors Know?

Market Chameleon (Tue, 19-May 10:19 AM)

ImmunityBio’s NAI+BCG Therapy Doubles Complete Response Durability Versus Nadofaragene in Bladder Cancer—New AUA 2026 Data Suggest Clinical Advantage

Market Chameleon (Tue, 19-May 7:54 AM)

IBRX Faces Class Action Lawsuit Amid Ongoing FDA Scrutiny Over Anktiva Drug Promotion

Market Chameleon (Fri, 15-May 11:26 AM)

MiNK Therapeutics Advances iNKT Cell Therapy Platform with Randomized Phase 2 Launch and Broad Clinical Progress

Market Chameleon (Fri, 15-May 7:40 AM)

ImmunityBio's Q1 2026 Revenue Surges 168% Year-over-Year as ANKTIVA Expands Globally

Market Chameleon (Thu, 7-May 8:17 AM)

ImmunityBio Spotlights ANKTIVA's Competitive Edge and Innovation in Bladder Cancer at AUA 2026

Market Chameleon (Tue, 5-May 8:05 AM)

ImmunityBio's ANKTIVA Enters Saudi Arabia Just Two Months After MENA Partnership: A New Option for Cancer Patients

Market Chameleon (Tue, 21-Apr 7:37 AM)

ImmunityBio Implements Enhanced Compliance Measures After FDA Inquiry—Stronger Protocols and Clearer Messaging for ANKTIVA®

Market Chameleon (Mon, 6-Apr 7:48 AM)

ImmunityBio Secures $100 Million in Financing—$75 Million Non-Dilutive Boost Sharpens Global Expansion and Pipeline Advancement

Market Chameleon (Tue, 31-Mar 7:51 AM)

ImmunityBio's Pivotal NMIBC Trial Achieves Key Milestone: No Additional Enrollment Needed for ANKTIVA Plus BCG Study

Market Chameleon (Thu, 26-Mar 7:50 AM)